56 results on '"Lennox Gastaut Syndrome"'
Search Results
2. Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
3. Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
4. A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, Teenagers and Adults in Portugal (DRALEGA-PT)
5. A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine
6. Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies (PACIFIC)
7. Epidyolex® in Lennox Gastaut and Dravet Syndrome: an Observational Study in ITALY (EpiTALY)
8. A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain (DRALEGA)
9. A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome
10. A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
11. BMB-101 in Absence Epilepsy and DEE
12. Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome (SOM-L)
13. An Extended Access Program (EAP) for Perampanel
14. A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
15. RNS System LGS Feasibility Study
16. An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
17. Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
18. Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
19. Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
20. Intermediate-Size Expanded Access Protocol (EAP) for LP352
21. EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children With Lennox Gastaut Syndrome (LGS)
22. A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
23. A Study of Soticlestat in Adults and Children With Rare Epilepsies (Endymion 1)
24. A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
25. Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy (FFA-LGS)
26. Children's Adaptive Deep Brain Stimulation for Epilepsy Trial (CADET): Pilot (CADET Pilot)
27. Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
28. Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
29. Long-term Cardiac Monitoring in Epilepsy (LOOP)
30. Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)
31. A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE4)
32. Investigation of Cognitive Outcomes With Cannabidiol Oral Solution (EPI-COG)
33. The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy (CBD1)
34. Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects
35. Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
36. An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes (GWPCARE5)
37. The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
38. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies (ELEKTRA)
39. Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome
40. Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
41. Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
42. A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
43. Epilepsy Phenome/Genome Project (EPGP)
44. Turmeric as Treatment in Epilepsy
45. Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome (LGS)
46. A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)
47. Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
48. Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome
49. Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study
50. European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.